CHA Bundang Medical Center reports sorafenib superiority in both PFS and OS based on large-scale real-world clinical analysis
[by Sung, Jae Jun] CHA University announced on December 1 that a research team led by Professors Chon Hong-jae and Kim Jeong-seon of the Department of Hemato-Oncology at CHA Bundang Medical Center (CBMC) has published the findings of the world's largest real-world clinical study analyzing 바카라 사이트 디시 treatment strategies for hepatocellular carcinoma (HCC) patients who experienced treatment failure with atezolizumab + bevacizumab (hereinafter referred to as A+B) treatment. The results were featured in the latest issue of JHEP Reports, an international journal in specializing hepatobiliary medicine.
The five-year survival rate for HCC in Korea remains low at 39.4%. Although the introduction of the A+B combination regimen has improved survival, many patients continue to experience disease progression, and evidence supporting 바카라 사이트 디시 treatment options remains limited. The previously held assumption that vascular endothelial growth factor receptor (VEGFR)-targeted therapies would demonstrate comparable efficacy has also been called into question.
The research team analyzed 230 of the 1,210 patients who received the A+B combination therapy between May 2018 and October 2019. Among them, 125 patients were treated with 바카라 사이트 디시 and 105 with sorafenib. Propensity score matching (PSM) was used to improve the reliability of the comparison between the two treatment groups.
The analysis showed that patients who received lenvatinib as 바카라 사이트 디시 therapy achieved a progression-free survival (PFS) of 5.5 months and an overall survival (OS) of 11.9 months, both significantly longer than those treated with sorafenib (PFS 2.6 months, OS 7.4 months). Overall survival measured from the start of the A+B therapy also differed notably, reaching 22.4 months in the Lenvatinib group compared with 14.3 months in the sorafenib group. This pattern was consistently observed in the PSM analysis and in the subgroup of patients who experienced primary failure on immunotherapy.
The research team noted that the study challenges the long-standing assumption of equivalence among VEGFR-targeted therapies and demonstrates that lenvatinib offers superior efficacy as a second-line treatment following failure of the A+B combination therapy. "Although this is an observational study, our analysis of a large, multinational patient dataset provides important evidence for determining treatment sequencing in real-world clinical practice. We expect this to represent a significant turning point in improving survival outcomes and establishing treatment standards for patients with hepatocellular carcinoma in the future," Chon stated.
Conversely, the study was carried out with support from the National Research Foundation of Korea’s Mid-career Researcher Support Program.